跳到正文
openFDA 已分级药品召回执法报告·· 19 天前AI 评分57

FDA 执法报告 D-0077-2027 收录 Macleods 奥美沙坦酯/氨氯地平/氢氯噻嗪片两批次溶出度不合格 II 类召回

FDA drug enforcement D-0077-2027: MACLEODS PHARMA USA, INC — Failed Dissolution Specifications.

AI 导读

openFDA 执法报告 D-0077-2027 显示,Macleods Pharma USA 的奥美沙坦酯、氨氯地平与氢氯噻嗪片 40 mg/10 mg/12.5 mg 因溶出度不符合标准被定为 II 类召回,由企业主动发起。

正文 · 原文

FDA drug recall enforcement report — D-0077-2027

Report issued: 2026-11-04. This is the enforcement report date, not the recall initiation date.

Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.

The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.

Complete official product record (including openFDA harmonized identifiers):

{

"address_1": "103 College Rd E Fl 2",

"address_2": "",

"center_classification_date": "20261026",

"city": "Princeton",

"classification": "Class II",

"code_info": "Lot #: a) 12251163A, Exp 05-31-2027; b) 12251163B, Exp 05-31-2027",

"country": "United States",

"distribution_pattern": "Nationwide in the USA",

"event_id": "100113",

"initial_firm_notification": "Letter",

"more_code_info": "",

"openfda": {

"application_number": [

"ANDA207088"

],

"brand_name": [

"OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE"

],

"generic_name": [

"OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE"

],

"is_original_packager": [

true

],

"manufacturer_name": [

"Macleods Pharmaceuticals Limited"

],

"nui": [

"N0000175359",

"N0000175419",

"M0471776"

],

"package_ndc": [

"33342-243-07",

"33342-243-10",

"33342-244-07",

"33342-244-10",

"33342-245-07",

"33342-245-10",

"33342-246-07",

"33342-246-10",

"33342-247-07",

"33342-247-10"

],

"pharm_class_cs": [

"Thiazides [CS]"

],

"pharm_class_epc": [

"Thiazide Diuretic [EPC]"

],

"pharm_class_pe": [

"Increased Diuresis [PE]"

],

"product_ndc": [

"33342-243",

"33342-244",

"33342-245",

"33342-246",

"33342-247"

],

"product_type": [

"HUMAN PRESCRIPTION DRUG"

],

"route": [

"ORAL"

],

"rxcui": [

"999967",

"999986",

"999991",

"999996",

"1000001"

],

"spl_id": [

"52c013e1-8c31-4bed-9241-e7845873ebe8"

],

"spl_set_id": [

"52c013e1-8c31-4bed-9241-e7845873ebe8"

],

"substance_name": [

"OLMESARTAN MEDOXOMIL",

"AMLODIPINE BESYLATE",

"HYDROCHLOROTHIAZIDE"

],

"unii": [

"6M97XTV3HD",

"0J48LPH2TH",

"864V2Q084H"

],

"upc": [

"0333342247070",

"0333342245076"

]

},

"postal_code": "08540-6611",

"product_description": "Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets 40 mg/10 mg/12.5mg, packaged as a) 30-count bottle, NDC 33342-246-07; b) 90-count bottle, NDC 33342-246-10; Rx Only, Manufactured for : Macleods Pharma USA, Inc. Princeton, NJ 08540, Manufactured by: Macleods Pharmaceuticals Ltd, Daman, 396210, India",

"product_quantity": "3528 30-count and 216 90-count bottles",

"product_type": "Drugs",

"reason_for_recall": "Failed Dissolution Specifications.",

"recall_initiation_date": "20261007",

"recall_number": "D-0077-2027",

"recalling_firm": "MACLEODS PHARMA USA, INC",

"report_date": "20261104",

"state": "NJ",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov